All these findings suggest a potential benefit of IL-1β-inhibitory therapies in the management of vascular aging, although further understanding of the mechanisms linking inflammation, IL-1β, endothelial dysfunction and cell senescence is needed. Here, IL1B is linked to endothelial dysfunction.